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A B S T R A C T
Cystic ﬁbrosis (CF) is an autosomal recessive, life-limiting condition characterized by progressive lung disease,
which is a major cause of morbidity and mortality for these patients. The inhalation therapy, OligoG CF-5/20, is
a low molecular weight (mean Mn 3200 g/mol) alginate oligomer, with a high guluronic acid content (> 85%).
The ability of OligoG CF-5/20 to enhance the activity of antimicrobial/antibiotic therapies, modify the rheo-
logical properties of CF sputum and interact with mucin, has previously been shown. To further characterize the
physicochemical interactions of OligoG CF-5/20 with CF sputum, Fourier-transform infrared (FTIR) spectro-
scopy was used to analyze ex vivo sputum samples from adolescent CF patients (n= 13) following treatment
with 0.2% OligoG CF-5/20. FTIR analysis conﬁrmed the interaction of OligoG CF-5/20 with mucin glycans in CF
sputum, which showed a shift in wavenumber from 1078 cm−1 to 1070 cm-1 and subsequent loss of the
1053 cm−1 peak in the OligoG CF-5/20 treated samples. OligoG CF-5/20 interaction with key terminal moieties
in mucin were also evident, with a signiﬁcant change in sulphation at wavenumber 1116 cm−1, suggesting a link
with sulphated Lewis x antigen. There were also signiﬁcant shifts at wavenumber 1637 cm-1 indicative of β-sheet
conformational changes in the mucin peptide caused by action of OligoG. The alterations in charge of glycan and
mucin structures support previous observations wherein OligoG CF-5/20 modiﬁes the viscoelastic properties of
CF sputum. These ﬁndings suggest a possible mechanism of action for the rheological changes observed with this
novel therapy.
1. Introduction
Cystic ﬁbrosis (CF) is an autosomal recessive disorder aﬀecting 1 in
2500 live births in the UK [1]. This life-limiting condition (median
predicted survival age ˜47 years) [2] is the result of mutations in the CF
transmembrane conductance regulator (CFTR) gene, characterized by
impaired epithelial chloride transport, leading to an abnormally viscous
mucous and poor lung clearance [3]. Obstructive pulmonary disease is
the primary cause of morbidity and mortality (˜80%) within CF patients
[4]. The ongoing cycle of infections caused by this thick, often stagnant,
mucus in the lung necessitates chronic use of antibiotics. Patients
eventually become colonized by multi-drug resistant (MDR) pathogens,
particularly Pseudomonas aeruginosa, leading to chronic inﬂammation
and reduced lung function [5]. Within the diseased CF lung, the
viscoelasticity of mucus is altered by constituents such as lipids, pro-
teins (e.g. IgM), DNA and mucins [6].
Mucins are a large glycosylated protein component of mucus [7].
Although mucins represent< 1% (w/v) of respiratory secretions
[8–10], they are important gel-forming constituents in CF sputum
[11–13]. They also play an important role in the innate immune system
[14] both as a physical barrier against chemical, enzymatic and me-
chanical insult, and by providing a ‘ﬁrst line’ of defense against pa-
thogens [15]. Whilst important in defense, mucin barriers may impede
drug delivery; with inhaled agents binding to the mucins and being
rapidly removed by mucociliary clearance [16]. Methods to disrupt
these muco-adhesive interactions, allowing crossing of the mucin-pro-
tective layer of the lung, would greatly improve drug delivery [17].
Alterations in terminal carbohydrate moieties are associated with
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respiratory disease and these modiﬁcations cause changes in the vis-
coelastic properties of the mucus, as the addition of charged residues
inﬂuences mucin aggregation [18]. CF mucins have been shown to
possess increased levels of fucose, galactose, N-acetylglucosamine [19],
sialic acid and sulphate [12]. Furthermore, increases in glycosylation
and branching in CF mucins have been shown to result in a higher
tendency to ‘gel’ and obstruct transport in vivo [19]. It has also been
demonstrated in CF that mucins may exhibit increased levels of ex-
pression of sialylated and sulphated-Lewis x determinants during in-
ﬂammation and infection [8]. The sulphated Lewis x antigen is the
main sulphated sugar in CF respiratory mucin [18]. Over sulphation in
CF respiratory and salivary mucins has long been reported in the lit-
erature [20–23].
OligoG CF-5/20 is a low molecular weight oligosaccharide derived
from the stem of brown seaweed, Laminaria hyperborea, and has re-
cently completed Phase 2b clinical trials (NCT02157922;
NCT02453789) as an inhalation therapy for CF patients. In previous in
vitro studies, treatment with G-rich alginate oligomers was shown to
alter the viscoelastic properties of mucin/alginate gels, mucin/DNA gels
and CF sputum [24,25]. OligoG CF-5/20 interacts with respiratory
mucins, inducing alterations in mucin porosity and surface charge [25].
It has also been shown to potentiate antibiotics against a range of multi-
drug resistant bacteria (up to 512-fold) [26]. Further studies have
conﬁrmed its ability to alter the surface charge of P. aeruginosa leading
to bacterial aggregation, a reduction in bacterial motility, and impaired
bioﬁlm formation [27,28]. High MW alginate as secreted by virulent CF
respiratory bacteria such as a mucoid P. aeruginosa, increase the elas-
ticity and viscosity of mucus, whilst conversely, low Mw alginates have
been shown to reduce the bulk elasticity and viscosity of mucus [29].
Interestingly, in vitro and in vivo studies have shown that low Mw al-
ginate oligosaccharides are able to displace mucin-high MW alginate
interactions, as might be expected to occur in the chronically infected
lung.
This study used Fourier-transform infrared spectroscopy (FTIR) to
examine direct physicochemical interactions of OligoG CF-5/20 with
respiratory mucins in order to better understand how it is able to alter
CF sputum viscosity. FTIR is a low-cost, high-throughput optical tech-
nology which requires only low volumes of test samples and has pre-
viously been employed to accurately characterize alterations in mucin
expression, secretion and glycosylation (as well as in the Lewis x an-
tigen structures) in respiratory disease [18,30,31].
The aim of this study was to use mucin infrared (IR) proﬁles from
our extensive spectral library (18), to identify key IR markers to de-
scribe the structural changes and electrostatic interactions that occur
within mucin glycan moieties and peptide backbone following OligoG
CF-5/20 treatment of CF sputum.
2. Materials and methods
2.1. Patient samples
Induced sputum samples were collected from cystic ﬁbrosis patients
after obtaining informed written consent (CF Sputum Induction Trial
[CF-SpIT] UKCRN: 14615). FTIR samples were collected from 13 pa-
tients (mean age 13.1 years; range 7–17 years; male to female ratio, 9:4
respectively). The mean FEV1 (% predicted) was 73 (range 31 to 99%)
with 69% of patients found to be infected with P. aeruginosa at the time
of sampling (Table 1). Samples were collected by expectoration, after
which they were stored by freezing at−80 °C. Prior to subsequent use,
sputum samples were defrosted overnight at 4 °C.
2.2. Fourier-transform infrared spectroscopy of cystic ﬁbrosis sputum
FTIR analysis was performed on CF patient sputum samples (n=13
patients; Table 1) + 0.2% OligoG CF-5/20 or dH2O; 0.2% OligoG CF-5/
20 reference spectra were also generated. CF sputum was incubated
with 0.2% (w/v) OligoG CF-5/20 or dH2O (control) for 4 h at 37 °C
[25]. 3 μl of each sample was pipetted in triplicate onto a 96-well si-
licon plate (Bruker Optics Inc., Coventry, UK). Following drying at
room temperature (1 h), high-throughput FTIR analysis was performed
using a Bruker Vertex 70 in transmission mode with a KBr beamsplitter,
DTGS detector and HTS-XT attachment. Spectra were acquired within
the range of 4000-400cm−1, at a resolution of 4 cm−1 with each
spectrum being the averaged result of 32 scans. Each silicon plate was
scanned in triplicate to ensure reproducibility of individual sample
spectra.
All data processing, analysis and visualizations were performed
using Bruker OPUS 7.5 software, and the R-statistical computing en-
vironment using in-built algorithms and code developed by our group.
The whole infrared spectra were pre-processed prior to further analysis
by baseline correction using the automatic ‘rubberband’ correction and
vector normalization. Absorbance spectra were smoothed using a nine-
point Savitzky-Golay algorithm and second derivative spectra were
calculated using a 9-point window. Based on our previously developed
mucin glycosylation IR spectral library (18), we assessed the ‘ﬁnger-
print’ spectral region (absorbance values between wavenumbers 1800
and 900 cm−1). Statistically signiﬁcant diﬀerences between peak po-
sitions or absorbance intensity at key wavenumbers in treated and
control CF sputum samples were determined using the Mann-Whitney U
Test. Multiple hypothesis testing was carried out on all statistical test
results using the Bonferroni correction. Whilst many potential wave-
numbers were investigated during this study, only those wavenumbers
which showed promise for determining interaction between OligoG CF-
5/20 were statistically examined. The following wavenumbers were
identiﬁed and statistically examined due to presence of peaks in treated
CF sputum spectra but not OligoG CF-5/20 spectra: 1652, 1637, 1240,
1116, 1080 and 1053 cm-1. Therefore, the corrected α-level was 0.008.
3. Results and discussion
FTIR was used to generate absorbance spectra between wave-
numbers 400 to 4000 cm−1 to establish biochemical changes following
0.2% (w/v) OligoG CF-5/20 incubation with CF sputum samples.
Analysis was then performed on IR wavenumbers within the 900 to
1800 cm−1 ‘ﬁngerprint’ region to focus on key structural changes in
mucin proteins and associated glycosylation. Fig. 1a shows the mean
absorbance spectra for both untreated and treated CF sputum samples
highlighting the wavenumber regions where IR absorbance patterns are
altered post-treatment. The spectra were aligned with a representative
OligoG CF-5/20 IR spectrum to easily identify regions of absorbance
change that occurred due to OligoG CF-5/20 being present in the
samples.
Raw absorbance IR spectra are a series of many peaks merged into
broad peaks to determine the exact position of peak changes between
untreated and OligoG CF-5/20 treated sputum spectra, whilst second
derivative spectra are used to enhance the separation of any over-
lapping peaks. Second derivative spectra were calculated and aligned
with that of OligoG CF-5/20 (Fig. 1b). Comparison of OligoG CF-5/20-
treated and -untreated CF sputum second derivative spectra with a
second derivative spectrum of 0.2% (w/v) OligoG CF-5/20 allowed
determination of potential structural changes or interactions at key
mucin peaks following OligoG CF-5/20 incubation of CF-patient
sputum.
3.1. Mucin glycan changes in the presence of OligoG CF-5/20
IR peaks associated with mucin glycan moieties, including sialylated
and sulphated Lewis x antigen, were initially assessed using known
wavenumber absorbance data from our glycosylation IR spectral library
[18]. Glycan associated structures, such as the CeO bonds in the pen-
tose and hexose rings, absorb strongly between 900 and 1280 cm−1,
with numerous second derivative peaks being evident. Unfortunately,
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OligoG CF-5/20 also absorbs strongly within the same region as mucin
glycans, with a number of key peaks identiﬁed at the same positions. As
we were interested in determining sputum mucin-OligoG CF-5/20 in-
teraction, and not just OligoG CF-5/20 presence in CF sputum, it was
necessary to focus our analysis on wavenumbers that showed diﬀer-
ences in absorbance, or peak presence which were not associated with
OligoG peaks, as being indicators of OligoG CF-5/20 interaction. For
example, Fig. 2a shows a second derivative peak at 1078 cm−1, in the
untreated sputum spectrum representing the major glycan-associated
peak, shifted to 1070 cm−1 in the OligoG CF-5/20 treated sputum
spectrum without a second derivative peak being evident in the OligoG
CF-5/20 spectrum at the same wavenumbers. Fig. 2b shows that the
distributions of major glycan-associated second derivative peak apex
positions for all samples in the OligoG CF-5/20 treated sputum spec-
trum were signiﬁcantly diﬀerent from the untreated control samples
(Table 2, P < 0. 008). We also observed that a peak at 1053 cm−1 was
completely lost following sputum treatment with OligoG CF-5/20, al-
though comparison with the OligoG CF-5/20 spectrum shows presence
of a peak maxima in the OligoG CF-5/20 spectrum. This suggests that
the second derivative peak loss at 1053 cm-1 may not be indicative of
interaction between OligoG CF-5/20 and the sputum mucins, rather it
could be indicative of OligoG CF-5/20 presence.
We next assessed the wavenumber region surrounding 1116 cm−1
which we had previously identiﬁed as probable absorbance from the
sulphated-Lewis x antigen [18]. Fig. 3a shows that absorbance at
1116 cm−1 was lost following OligoG CF-5/20 treatment, suggesting an
interaction of OligoG CF-5/20 with the sulphated-Lewis x antigen.
Fig. 3b, summarized in Table 2 shows signiﬁcant diﬀerences across all
samples between treated and untreated for 1116 cm−1. We also ex-
amined absorbance at, and peak positions around, 1240 cm−1 which is
Table 1
Patient data for sputum samples used for FTIR in this study.
Patient Age (Years) Sex Antibiotics Cultured Pathological Bacteria (Isolated in past 12
months)
FEV1 % predicted (Z score) BMI centile (Z score)
1 16 M AZM, FLC H. inﬂuenzae, S. aureus, S. maltophilia, 62 (-3.2) 25 (-1.2)
2 17 M AZM, CSTIV, FLC, DOX, MEMIV,
TOBneb
H. inﬂuenza, S. aureus, S. maltophilia, * 9 (-1.93)
3 14 F AZM, CLR, ETB, RIF S. maltophilia 64 (-3.0) 9 (-1.7)
4 15 F AZM, CLMneb FLC P. aeruginosa 87 (-1.1) 50 (0.42)
5 15 M AZM, CLMneb FLC P. aeruginosa, S. aureus 75 (-2.0) 25 (-0.99)
6 9 M AZM, FLC, CLMneb/TOBneb S. marcescens, S. aureus 84 (-1.3) 91 (1.23)
7 16 F AZM, CLMneb H. parainﬂuenzae 64 (-2.9) 25 (-0.53)
8 14 M CLR, MIN, MEMneb, MXF M. abscessus 57 (-3.5) 50 (0.2)
9 14 M AZM H. inﬂuenzae, MRSA, S. aureus 64 (-2.9) 91 (1.23)
10 11 M AZM, CLMneb P. aeruginosa, MRSA 47 (-4.5) 50 (-0.49)
11 11 F B. cenocepacia 99 (-0.1) 98 (1.96)
12 12 M AZM P. aeruginosa (mucoid) 78 (-1.8) 50 (0.34)
13 7 M AZM, FLC, CLMneb/TOBneb B. cenocepacia, P. aeruginosa, S. maltophilia, S. aureus 81 (-1.5) 91 (1.85)
Abbreviations: BMI centile, body mass index (kg/m2) centile; FEV1, forced expiratory volume in one second; IV, intravenous antibiotic; Neb, nebulised antibiotic.
Antibiotics: AZM, azithromycin; CLR, clarithromycin; CST, colistin; CLM, colomycin; DOX, doxycycline; ETB, ethambutol; FLC, ﬂucloxacillin; MEM, meropenem;MIN,
minocycline; MXF, moxiﬂoxacin; RIF, rifampicin; TOB, tobramycin.
Bacteria: B. cenocepacia, Burkholderia cenocepacia; H. inﬂuenzae, Haemophilus inﬂuenzae; H. parainﬂuenzae, Haemophilus parainﬂuenzae; M. abscessus, Mycobacterium
abscessus; M. avium-intracellulare, Mycobacterium avium-intracellulare, P. aeruginosa, Pseudomonas aeruginosa; S. aureus, Staphylococcus aureus; S. maltophilia,
Stenotrophomonas maltophilia; S. marcescens, Serratia marcescens; MRSA, methicillin resistant S. aureus.
* Missing data.
Fig. 1. Raw absorbance and second derivative infrared spectra
for untreated and OligoG CF-5/20- treated sputum. (a) Mean
IR spectra from the 1800 cm−1 to 1000 cm−1 IR wavenumber
region of: untreated CF sputa; treated CF sputa; OligoG CF-5/
20 in water. (b) Second derivative spectra for the above (note
that peaks are negative and point down in second derivative
IR spectra). Treated sputum, solid grey line; untreated
sputum, black dashed line; OligoG CF-5/20, light-grey dashed
line.
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also indicative of absorbance by the sulphated-Lewis x antigen (Fig. 4a).
A general but small shift in peak position towards lower wavenumbers
in the OligoG CF-5/20 incubated sputum spectra, relative to untreated
control sputum spectra (Fig. 4b) was observed. Additionally a small
decrease in absorbance was observed at 1240 cm−1 in the incubated
sputum spectra (Fig. 4c). Although this could suggest a likely interac-
tion between OligoG CF-5/20 and sulphated-Lewis x antigen, the de-
crease in absorbance at 1240 cm−1 in the incubated sputum spectra,
and the peak shift were not found to have statistical signiﬁcance.
Within sputum, negatively-charged biopolymers such as mucin,
DNA and alginates, assemble via physical entanglement of non-covalent
bonds. As glycoproteins exhibit electrostatic, hydrophobic and hy-
drogen bonding interactions, mucin is able to readily adhere to other
substances. Modiﬁcation of the glycan chains of CF mucins has pre-
viously been hypothesized to increase bacterial binding and coloniza-
tion in the CF lung. Alteration in mucin glycosylation has been de-
monstrated to potentiate P. aeruginosa binding to CF mucins when
compared to non-CF mucins [32]. Glycan sulphation may increase with
bacterial infection, possibly to protect the underlying glycoproteins
from enzymatic degradation by bacteria [33]. Both inﬂammatory leu-
kocytes and P. aeruginosa are thought to recognize sulphated ligands
and lead to an inﬂammatory response and increased pathogenesis of P.
aeruginosa respectively [21,34]. Interestingly, increases in sulphation
have been demonstrated in the absence of bacterial infection in CF,
suggesting this may be a primary defect of the disease [35,36]. How-
ever, other studies have reported a reduction in sulphation in CF pa-
tients when compared to healthy controls, leading some to dispute its
signiﬁcance in CF patients [37]. Nevertheless, changes in the sulphation
peak in sputum observed in the current study suggest that OligoG CF-5/
20 was able to bind to the sulphate moieties on the glycans, and in this
way counteract the eﬀects of pathogen recognition and binding [36].
Reducing barriers to drug and gene delivery [38,39] and modifying
the properties of mucus may be beneﬁcial in a range of clinical con-
ditions such as CF [40], and reproductive medicine [41]. Although
mucin generally serves as a barrier to bacteria, several pathogens such
as P. aeruginosa reside within mucus and possess mucin-speciﬁc ad-
hesins [17]. Mucin interactions with P. aeruginosa have been shown to
increase bacterial motility, which is partly directed by both quorum
sensing (QS) and the physical properties of mucin [42]. In contrast,
OligoG CF-5/20 has been shown to bind to the cell surface of P. aeru-
ginosa, modifying its QS signaling pathways and reducing its motility
[26,28,43].
3.2. Mucin protein back bone changes in the presence of OligoG CF-5/20
To determine possible mucin peptide backbone alterations fol-
lowing incubation with OligoG CF-5/20, we examined the Amide I re-
gion between wavenumbers 1628 cm−1 and 1664 cm−1 (Fig. 5a). This
range was selected to include those peaks related to the random coil
(1652 cm-1) and β-sheet (1637 cm-1) secondary structures that pre-
dominate in sputum mucins and to avoid amino sugar absorbance at
1626 cm−1 [30]. Through FTIR analysis of these wavenumbers, we
have previously shown OligoG CF-5/20 is capable of binding to mucin
[25]. Binding between OligoG CF-5/20 and CF mucins was also pre-
viously characterized using FTIR, demonstrating an interaction be-
tween OligoG CF-5/20 and the carbonyl group within the peptide link
Fig. 2. Mean second derivative spectra for OligoG CF-5/20 treated and untreated sputum within the 1040 cm−1 to 1090 cm−1 wavenumber range indicating IR
absorbance from mucin glycans and OligoG CF-5/20. (a) The IR peak at 1078 cm−1 shifted to 1070 cm−1 following OligoG CF-5/20 incubation and the peak at
1053 cm−1 in the untreated spectrum was completely lost. (b) Boxplots of peak positions between 1080 cm−1 and 1060 cm−1 show the distributions of second
derivative peak apex positions centered around 1078 cm−1 and 1070 cm−1 in untreated and treated samples respectively. Treated sputum, solid grey line; untreated
sputum, black dashed line; OligoG CF-5/20, light-grey dashed line. *P < 0.008, mean of n= 3 replicates.
Table 2
Results of Paired Mann-Whitney signed rank tests for diﬀerences of means in absorbance intensity at the speciﬁed wavenumbers, and peak position around the
selected wavenumbers.λ=<0.008 mean of n= 3 replicates.
Wavenumbers (cm−1) Peak Shift or Absorbance Change Mean Diﬀerence (Control – Treated) p-value
1652 Second Derivative Peak Shift 0.3563 (cm−1) 0.5416
Second Derivative Absorbance Change 3.246958* 10 −6 (AU) 0.4731
1637 Second Derivative Peak Shift 0.3518 (cm−1) 0.0580
Second Derivative Absorbance Change −2.016733 * 10 -5 (AU) 0.0342
1240 Absorbance Peak Shift 0.0788 (cm−1) 0.3910
Absorbance Change in Treated Group 0.00094 (AU) 0.0078 λ
1116 Second Derivative Peak Loss in Treated CF Sputum NA 3.436 * 10−11 λ
Second Derivative Absorbance Change −2.795417 * 10-5 (AU) 7.105 * 10−15 λ
1078 Second Derivative Peak Shift −2.9444 (cm-1) 0.00012 λ
Second Derivative Absorbance Change −2.186917 * 10-5 (AU) 2.08 * 10−8 λ
1053 Second Derivative Peak Loss in Treated CF Sputum NA 0.00001
Second Derivative Absorbance Change −1.323538 * 10-5 (AU) 1.052 * 10−10 λ
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of the mucin protein backbone found in the Amide I region [25]. It is
possible that the experimental conditions, namely the drying of the
sputum to form a thin ﬁlm, could inﬂuence the protein secondary
structure and therefore the peak positions. However, there are a
number of publications which show that comparable protein secondary
structure information is derived from circular dichroism and FTIR
based experiments on protein solutions and on thin ﬁlms [44–47].
Therefore, it is reasonable to hypothesise that the experimentally
required drying of the sputum was unlikely to cause alterations to the
secondary structure of the mucins in our current study.
In the present study, we did not observe statistically signiﬁcant
(P > 0.008) shifts in peak position around 1652cm−1 (Fig. 5b i-iii),
and we could not observe a statistically signiﬁcant decrease in second
derivative peak height at 1637 cm−1 (P < 0.05, but P > 0.008) in the
OligoG CF-5/20 treated samples (Fig. 5c iii). It is probable that the
small sample size used in the current study may contribute towards this
Fig. 3. Mean second derivative spectra for
OligoG CF-5/20 treated and untreated sputum
surrounding 1116 cm−1 indicating IR absor-
bance from sulphated-Lewis x antigen. (a) The
IR peak at 1116 cm−1 was lost following
OligoG CF-5/20 incubation. The new peak oc-
curring at 1096 cm−1 in the treated spectrum
is suggestive of interaction between OligoG CF-
5/20 and sulphated- sulphated-Lewis x an-
tigen. (b) Boxplots of second derivative nega-
tive peak height distributions centered around
1116 cm−1 in untreated and treated samples
respectively. Treated sputum, solid grey line;
untreated sputum, black dashed line; OligoG
CF-5/20, light-grey dashed line. *P < 0.008,
mean of n=3 replicates.
Fig. 4. Mean raw absorbance at
1240 cm−1. (a) Mean treated and un-
treated spectra showing lower absor-
bance in the treated spectrum. Boxplots
showing the distribution of (b) wave-
number and (c) relative absorbance in
untreated and treated samples centered
around 1240 cm−1. Treated sputum,
solid grey line; untreated sputum, black
dashed line; OligoG CF-5/20, light-grey
dashed line. *P < 0.008, mean of
n=3 replicates.
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lack of signiﬁcance. Previous molecular modelling observations have
shown that OligoG is able to alter the structure of mucus and modulate
mucin assembly [25]. We hypothesized this to be as a result of hy-
drogen bonding between OligoG CF-5/20 and the peptide backbone
causing a conformational change in the β-sheet secondary structure of
the peptide backbone. The closeness to signiﬁcance shown in the cur-
rent study is promising and a larger study may demonstrate sig-
niﬁcance. We also hypothesize that steric hindrance may have con-
tributed to the lack of signiﬁcant change noted between OligoG CF-5/
20 incubated sputum and control sputum spectra at the random coil
associated wavenumber, 1652 cm−1.
3.3. Clinical data analysis
The use of portable FTIR has recently been shown to predict acute
episodes of chronic obstructive pulmonary disease (COPD) [18] and to
the facilitate detection of lung cancer [31,48–50]. A potential role for
FTIR in CF is not unreasonable given the changes seen in CF mucus with
DNA, F-actin, mucin structure, and rheology, which have been asso-
ciated with pulmonary exacerbations [51].
All patients (except one) who provided induced sputum samples
were taking antibiotics (Table 1). No correlation was found between the
wavenumber changes reported here and antibiotic use, sex, age, use of
rhDNase I or forced expiratory volume in 1 s (FEV1).
FTIR analysis, however, does have limitations: It cannot determine
the exact molecular structure of compounds, and some vibrations de-
tected by FTIR are attributable to multiple chemical groups. These
limitations are being overcome by the development of an FTIR
reference library for monosaccharides [18]. Moreover, the IR spectral
pattern of untreated CF sputum within the ﬁngerprint region in the
current study were shown to be highly similar to that seen in sputum
from COPD patients [18]. As sialylation and sulphation of the Lewis x
antigen is associated with respiratory disease, FTIR could be further
developed to monitor the treatment of CF patients, and identify po-
tential mucosal changes prior to pulmonary exacerbations [18]. How-
ever, there is considerable heterogeneity in CF sputum samples, so
experiments should be performed with suﬃcient replication to identify
potential outliers [19]. Despite this inherent heterogeneity, FTIR ana-
lysis in the current study showed remarkable intra-sample reproduci-
bility, and conﬁrmed key speciﬁc binding sites for OligoG CF-5/20 with
mucin glycan moieties and the peptide backbone.
4. Conclusion
These ﬁndings demonstrate the use of FTIR analysis to study the
interaction of alginate OligoG CF-5/20 with glycan moieties and the
peptide backbone of mucin molecules in CF sputum. As increases in
sulphation within CF mucins are associated with infection and reduced
pulmonary function, this ﬁnding suggests a potential mechanism
whereby OligoG CF-5/20 modiﬁes the viscoelastic properties of CF
sputum.
It is known that patients with cystic ﬁbrosis have sub-optimal ad-
herence to long-term inhaled therapies, but this can be improved
through the use of electronic monitoring [52]. The current study shows
how a simple FTIR-based protocol can be utilized to detect interaction
between OligoG CF-5/20 and sputum mucins. It is feasible that FTIR
Fig. 5. Mean second derivative spectra for
OligoG CF-5/20 treated and untreated sputum
within the Amide 1 region between 1628 cm−1
and 1664 cm-1. (a) A wavenumber shift at
1652 cm-1 related to random coil secondary
structure and absorbance change at 1637 cm-1
related to β-sheet structure were observed. (b)
Boxplots showing the distribution of peak po-
sitions in untreated and treated samples cen-
tered around i)1652 cm-1 and ii) 1637 cm-1. (c)
Boxplots showing the distribution of second
derivative absorbance in untreated and treated
samples centered around i)1652 cm-1 and ii)
1637 cm-1. Treated sputum, solid grey line;
untreated sputum, black dashed line; OligoG
CF-5/20, light-grey dashed line.
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analysis could be employed to monitor patient adherence to therapy
through detection of OligoG CF-5/20 in expectorated sputum, and
allow healthcare providers to give additional support to patients who
show poor compliance with essential treatments.
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